Synthesis and pharmacological evaluation of new arylpiperazines N-{4-[4-(aryl) piperazine-1-yl]-phenyl}-amine derivatives: Putative role of 5-HT1A receptors

Bioorganic and Medicinal Chemistry

Volumn 17, Issue 5, 2009, Pages 1890-1897

  Khatri, Manisha ^a   Rai, Santosh Kumar ^a   Alam, Sameena ^a   Vij, Anjana ^b   Tiwari, Manisha ^a  

^a UNIVERSITY OF DELHI   (India)

^b DEFENCE INSTITUTE OF PHYSIOLOGY AND ALLIED SCIENCES   (India)

Author keywords

5 HT1A Receptor agonist antagonist; Anxiolytic like activity; Elevated plus Maze; Serotonin receptors

Indexed keywords

BUSPIRONE; DIAZEPAM; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N [4 (4 PHENYLPIPERAZIN 1 YL)PHENYL]CARBAMIC ACID ETHYL ESTER; N [4 [4 (2 METHOXYPHENYL)PIPERAZIN 1 YL]PHENYL]CARBAMIC ACID ETHYL ESTER; PIPERAZINE DERIVATIVE; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BRAIN TISSUE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; MALE; MAZE TEST; NONHUMAN; RAT; TASK PERFORMANCE; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; CARBAMATES; MALE; MOTOR ACTIVITY; PIPERAZINES; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN;

EID: 61349100285     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2009.01.043     Document Type: Article

References (25)

1. Eisenberg D.M., Davis R.B., Ettner S.L., Appel S., Wilkey S., Van Rompay M., and Kessler R.C. JAMA 280 (1998) 1569
2. Den Boer J.A., Bosker F.J., and Slaap B.R. Hum. Psychopharmacol. 15 (2000) 315
3. Clement Y., and chapouthier G. Neurosci. Biobehav. Rev. 22 (1998) 623
4. Hoyer D., Hannon J.P., and Martin G.R. Pharmacol. Biochem. Behav. 71 (2002) 533
5. Celada P., Puig M., Amargos-Bosch M., Adell A., and Artigas F. J. Psychiatry Neurosci. 29 (2004) 252
6. Fulton B., and Brogden R.N. CNS Drugs 7 (1997) 68
7. Obniska J., Kolaczkowski M., Bojarski A.J., and Duszyńska B. Eur. J. Med. Chem. (France) 41 7 (2006) 874
8. Glennon R.A., Dukat M., and Westkaemper R.B. In: Bloom F.E., and Kupfer D.J. (Eds). Psychopharmacology: The Fourth Generation of Progress. CDROM ed. (1999), Raven Press, New York
9. Kossakowski J., Struga M., and Koziol A.E. Acta Pol. Pharm. (Poland) 63 4 (2006) 255
10. Glennon, R. A.; Dukat, M. Serotonin ID Research Alert 1997, 2, 351.
11. Dawson G.R., and Tricklebank M.D. Trends Pharmacol. Sci. 16 (1995) 33
12. Hovatta I., Tennant R.S., Helton R., Marr R.A., Singer O., Redwine J.M., Ellison J.A., Schadt E.E., Verma I.M., Lockhart D.J., and Barlow C. Nature 438 (2005) 662
13. Thornalley P.J. Trends Mol. Med. 12 (2006) 195
14. Kromer S.A., et al. J. Neurosci. 25 (2005) 4375
15. De Vry J. Psychopharmacology 121 (1995) 1
16. Forster E.A., Cliffe I.A., Bill D.J., Dover G.M., Jones D., Reilly Y., and Fetcher A. Eur. J. Pharmacol. 281 (1995) 81
17. Senkowski D., Linden M., Zubragel D., Bar T., and Gallinat J. J. Biol. Psychiatry 53 (2003) 304
18. Griebel G. Pharmacol. Ther. 65 (1995) 319
19. Voigt J.P., Rex A., Sohr R., and Fink H. Eur. Neuropsychopharmacol. 9 (1999) 279
20. Rex A., Marsden C.A., and Fink H. Psychopharmacology 110 (1993) 490
21. Walf A.A., and Frye C.A. Nat. Protocols 2 (2007) 322
22. Racker E. J. Biol. Chem. 190 (1951) 685
23. Carlberg J., and Mannervik B. J. Biol. Chem. 250 (1975) 5475
24. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. J. Biol. Chem. 193 (1951) 265
25. Sperk G. J. Neurochem. 38 (1982) 840